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Abstract
Background: Pancreatic cancer is a very aggressive disease with dismal prognosis; peculiar is the tumor microenvironment
characterized by an extensive fibrotic stroma, which favors rapid tumor progression. We previously reported that pancreatic
cancer patients have a selective Th2 skew in the anti-carcinoembryonic antigen (CEA) CD4
+ T cell immunity, which
correlates with the presence of a predominant GATA-3
+ tumor lymphoid infiltrate. This has negative effects in both effective
anti-tumor immunity and further favoring fibrinogenesis. Aim of this study was to evaluate whether the Th2 polarization of
CEA-specific CD4
+ T cells from pancreatic cancer patients is stable or can be reverted by immunomodulating cytokines.
Methodology/Principal Findings: We first evaluated the influence of IL-12 and IL-27, as single agents and in association, on
the polarization of CEA-specific Th2 CD4
+ T cell clones from a pancreatic cancer patient. We found that only the
combination of IL-12 and IL-27 modified the polarization of Th2 effectors by both reduction of IL-5, GM-CSF and IL-13 and
induction of IFN-c production, which lasted after cytokine removal. Second, we evaluated the effect of the combined
treatment on polyclonal CEA-specific CD4
+ T cells in short-time re-stimulation assays. In agreement with the data obtained
with the clones, we found that the combined treatment functionally modulated the Th2 polarization of CEA-specific CD4
+ T
cells and enhanced pre-existing Th1 type immunity.
Conclusions/Significance: Collectively, our results demonstrate that tumor antigen specific Th2 CD4
+ T cells in pancreatic
cancer are endowed with functional plasticity. Hence, loco-regional cytokines delivery or targeted therapy based on
antibodies or molecules directed to the tumor stroma might improve anti-tumor immunity and ameliorate fibrosis, without
systemic toxicity.
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Introduction
Pancreatic cancer (PC) is a very aggressive disease with dismal
prognosis [1]. Peculiar is the tumor microenvironment, which
consists of fibroblasts, pancreatic stellate cells, endothelial cells,
immune and endocrine cells and perineural spreading and it is
believed to play an active role in disease progression and
aggressiveness [2].
Recently [3], we investigated the quality of the anti-tumor
CD4
+ T cell responses in PC patients undergoing surgical
resection, by comparing the anti-carcinoembryonic (CEA) and
anti-viral CD4
+ T cell immunity. We found that anti-CEA CD4
+
T cell immunity was present in a significantly lower number of PC
patients compared to normal donors. Most importantly, while
CD4
+ T cells from normal donors produced mainly granulocytes
macrophages colony stimulating factor (GM-CSF) and the pro-
inflammatory (i.e., Th1) cytokine interferon-c (IFN-c), CD4
+ T
cells from the patients produced mainly interleukin(IL)-5 and IL-
13, demonstrating a skew towards an anti-inflammatory (i.e., Th2)
type. On the contrary, the extent of anti-viral CD4
+ T cell
immunity was comparable between the two groups and showed a
Th1 type. In agreement with the Th2 skew observed in circulating
CEA specific CD4
+ T cells, immunohistochemical analysis of
tumor infiltrating lymphocytes showed a significantly higher
number of GATA-3
+ (Th2) compared to T-bet
+ (Th1) lymphoid
cells, supporting a Th2 skew also at the tumor site.
It has been shown that fibrosis, which is a hallmark in PC, is
strongly linked to the development of Th2 responses through
activation by Th2 cytokines of collagen synthesis by fibroblasts and
concomitant reduced collagen degradation in the absence of Th1
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+ lymphoid cells,
which we observed [3] in the pancreatic tumor microenvironment,
might further contribute to fibrosis and local treatments aimed at
reducing the presence of Th2 cytokines might be beneficial.
Among the various factors that promote CD4
+ T cells
polarization, cytokines have a determinant role [5]. IL-12, a
product of phagocytes and dendritic cells in response to microbial
stimulation, has a major role in promoting Th1 polarization and in
enhancing CD4
+ T cells proliferation [6]. Moreover, IL-12 has
been shown to induce reversal of Th2 polarization in human
allergen-specific Th2 cells [7,8] and, in synergy with IL-18, to
stimulate IFN-c production of peripheral blood mononuclear cells
(PBMC) from lepromatous leprosy patients [9]. IL-27, a recently
identified member of the IL-12 family [10], also stimulates
proliferation and synergizes with IL-12 in triggering IFN-c
production of naı ¨ve CD4
+ T cells [10,11]. More recently, it has
been shown [12] that IL-27 inhibits Th2 polarization of naı ¨ve
murine CD4
+ T cells and suppresses Th2 cytokines production
from in vitro polarized Th2 cells.
In the present study we investigated the possibility to revert the
Th2 polarization of bona fide in vivo primed CEA-specific CD4
+ T
cells from PC patients by using IL-12 and IL-27 as immunomod-
ulating agents. We found that the presence of IL-27 alone was
sufficient to inhibit IL-5 and IL-13 secretion, while IL-12 strongly
stimulated IFN-c production with minor effects on Th2 cytokines
secretion; the combination of the two cytokines induced a
functional modulation of the Th2 polarization.
Materials and Methods
Subjects and cell lines
PBMC were obtained from two PC patients (pt#15 and pt#43)
and one healthy donor (ND#11) of a cohort of subjects in which
we previously detected anti-CEA CD4
+ T cells [3]. Patients were
drawn before surgery and staging of the disease was T3N1M0 in
both cases. The Institutional Ethics Committee (Comitato Etico
Fondazione Centro San Raffaele del Monte Tabor, Istituto
Scientifico Ospedale San Raffaele) had approved the study
protocol and written informed consent was obtained from all
donors before blood sampling. EBV-transformed lymphoblastoid
cell lines (LCL) used and their human leukocyte antigen (HLA)-
DR type were: SKP-LCL (b1*0405, *1401; b3*02), established in
our laboratory from a healthy donor; BM21 (b1*1101; b3*0202)
and Pitout (b1*0701; b4*0101), kindly provided by K. Fleisch-
hauer (San Raffaele Scientific Institute, Milan). LCL were cultured
in RPMI 1640 (BioWhittaker) containing 2 mM L-glutamine,
100 units/ml penicillin, 50 mg/ml streptomycin (BioWhittaker),
and 10% FCS (BioWhittaker).
Synthesis of CEA peptides
CEA99–111, CEA117–129, CEA177–189/355–367, CEA425–437,
CEA568–582, and CEA666–678 sequences were synthesized by the
stepwise solid-phase method as previously described [13]; the
peptides were lyophilized, reconstituted in DMSO (Sigma-Aldrich)
at 10 mg/ml and diluted in RPMI 1640 as needed.
In vitro propagation of CD4
+ T cell clones
Polyclonal CEA177–189/355–367 specific CD4
+ T cells from
pt#15, obtained after 13 days of short-term culture with the
specific peptide and autologous CD4
+-depleted PBMC as antigen
presenting cells (APC), were cloned by limiting dilution as
described in [14]. The clones were cultured in X-VIVO 15
(BioWhittaker) supplemented with 5% heat-inactivated pooled
human serum (BioWhittaker), penicillin (100 U/ml; BioWhit-
taker), streptomycin (50 mg/ml; BioWhittaker), and IL-2
(250 IU/ml; Proleukine, Novartis). Clones were re-stimulated
every 15–21 days with phytohemagglutinin (PHA) (0,5 mg/ml;
Sigma-Aldrich) and irradiated allogenic PBMC.
CD4
+ T cell clones stimulation assay
CD4
+ T cells (10
4/well) were cultured in triplicate in 96-U
bottom plates in the presence of irradiated LCL (5610
4/well), or
irradiated autologous or HLA-DRb3*02 matched PBMC (10
5/
well) as APC pulsed with the CEA177–189/355–367 peptide (10 mg/
ml), or the purified CEA protein (30 mg/ml, BiosPacific), or
normal human IgG (30 mg/ml, Venimmun N, Aventis Behring),
as negative control. In inhibition experiments the following
monoclonal antibodies (mAbs) (Beckton Dickinson) were used:
anti-HLA-DR (100 ng/ml), anti-HLA-DP (3 mg/ml) and anti-
HLA-DQ (125 ng/ml). In peptide titration experiments, the
following concentrations of peptide were added: 20-10-5-1-0,5-
0,1-0,05-0,01 and 0,005 mg/ml. In the experiments with immu-
nomodulatory cytokines, recombinant human IL-12 and/or IL-27
(R&D Systems Inc.) were added at the following concentrations:
IL-12, as single agent (5–20 ng/ml); IL-27, as single agent (0,01-1-
10-100 ng/ml); combined IL-12 and IL-27 treatment (5 ng/
ml+100 ng/ml, respectively). After 48 h, supernatant from each
well was removed and pooled for cytokines’ detection by ELISA,
according to the manufacturers’ instructions: GM-CSF (sensitivity
threshold: 31,25 pg/ml) and transforming growth factor (TGF)-b1
(sensitivity threshold: 62,5 pg/ml) (Biosource International Inc.);
IFN-c, IL-5 and IL-13 (sensitivity threshold: 15,6 pg/ml) (Mab-
tech) and IL-17 (eBioscience) (sensitivity threshold: 7,8 pg/ml).
IFN-c, tumor necrosis factor (TNF)-a, IL-10, IL-4, IL-5 and IL-2
release was also determined by using the Cytometric Beads Array
(CBA) Human Th1-Th2 Cytokines Kit (sensitivity threshold:
20 pg/ml), (Becton Dickinson), following the manufacturer’s
instructions.
Short-term culture and cytokine release assay
Purified CD4
+ T cells were stimulated once in vitro in the
presence of the CEA peptides as previously described [3]. Briefly,
CD4
+ T cells (3610
4/well), purified from total PBMC by
magnetic beads (Miltenyi Biotec), were plated in 96-well plates
in five replicates for each condition and cultured in X-VIVO 15
supplemented with penicillin (100 U/ml), streptomycin (50 mg/
ml) and 3% heat-inactivated pooled human serum (tissue culture
medium, TCM), in the presence of irradiated CD4
+-depleted
PBMC as APC, at a CD4
+: APC ratio of 1:3. Stimuli were: PHA
(10 mg/ml; Sigma-Aldrich), as positive control; CD4
+ T cells in the
presence of the APC only, as baseline (blank); and each single
peptide (10 mg/ml). Recombinant human IL-12 (5 ng/ml) and IL-
27 (100 ng/ml) were added where indicated. At day 7, half
medium from each well was removed and replenished with fresh
TCM containing IL-2 (25 IU/ml), and IL-12 and IL-27 where
indicated, without any further antigen stimulation. At day 14,
supernatant was collected for IFN-c, IL-5, IL-13 and GM-CSF
release by ELISA, as described above.
Flow cytometry
Cytofluorimetric analyses were performed on a FACSCalibur
and analyzed using the FlowJo software (Tree Star, Inc.). The
following antibodies were used: anti-CD3-APC, anti-CD4-PercP,
anti-CCR4-PE, anti-CCR5-FITC (Pharmingen) and anti-
CRTH2-PE (Miltenyi Biotec). TCRVb expression was determined
with the IO Test Beta Mark kit (Immunotech), following the
manufacturer’s instruction.
Modulation of Th2 Polarization
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Characterization of CEA177–189/355–367 specific
Th2-cytokines producing CD4
+ T cell clones
We previously reported that PC patients have a Th2 skew in anti-
CEA CD4
+ T cell immunity while maintaining an intact repertoire of
anti-viral Th1 cells [3]. To better characterize the feature of this anti-
CEA response we cloned by limiting dilution CEA177–189/355–367
specific polyclonal CD4
+ Tc e l l sf r o mp t#15, obtained after an in vitro
short-term re-stimulation of CD4
+ T cells with autologous APC pulsed
with the relevant peptide; an assay that we previously showed not to
favor in vitro priming [15]. Polyclonal cells produced high levels of IL-5
and very little of GM-CSF but no IFN-c[3], suggesting the presence of
in vivo primed CD4
+ T cells with Th2 features. Two clones were
obtained, which expressed the same T cell receptor (TCR) Vb chain,
i.e. the Vb17 (Fig. 1E), and therefore we used them indifferently in the
following experiments being bona fide the same clone.
The characterization of the CEA177–189/355–367 specific CD4
+ T
clones is depicted in Figure 1. CD4
+ T cell clones produced mainly
IL-5, IL-13 and GM-CSF, while they released low amount of IL-4,
and IFN-c and no IL-2, TNF-a, TGF-b1, IL-10 or IL-17 (Fig. 1A).
Although the cells produce little amount of IL-4, this pattern of
cytokine secretion is consistent with a Th2 polarization.
To identify the restriction element we first tested the recognition by
CD4
+ T cells of peptide loaded autologous APC in the absence or in
t h ep r e s e n c eo fa n t i - H L A - D R ,a nti-HLA-DP and anti-HLA-DQ
mAbs. As shown in Fig. 1B (upper panel), addition of the anti-DR mAb
inhibited (65,5%) IL-5 production by CD4
+T cells, demonstrating that
an HLA-DR molecule presented the peptide.To identifythe HLA-DR
presenting allele, the cells were then challenged with the relevant
peptide in the presence of LCL expressing different combinations of
the HLA-DRb1, b3a n db4 alleles expressed by the patient (indicated
in Fig. 1B) and tested for IL-5 release. As shown in Fig. 1B (lower
panel), CD4
+ T cells recognized the peptide in association with HLA-
DRb3*02, which is the allele shared between the patient and the two
presenting LCL (BM21 and SKP).
We also performed peptide titration curve in which CD4
+ T
cells were challenged with increasing concentration of the relevant
peptide (Fig. 1C). The experiments indicated the expression by the
clone of a very low affinity TCR.
We previously showed that CEA sequence repeated at positions
177–189 and 355–367 contains an in vitro naturally processed epitope
presented in association with several HLA-DR alleles [16]. To confirm
these data, CD4
+ T cell clones were challenged with the CEA protein
or normal human IgG, as a negative control, and assayed for IL-13
r e l e a s e .A ss h o w ni nF i g .1 D ,C D 4
+ T cells specifically produced IL-13
i nt h ep r e s e n c eo ft h ep e p t i d ea n d ,m o s ti m p o r t a n t l y ,i nt h ep r e s e n c eo f
theCEAbut not ofthe controlprotein (i.e.,human IgG),demonstrating
that although CEA177–189/355–367 specific CD4
+ T cell clones carry a
low affinity TCR they recognize the native epitope.
Finally, to verify whether the Th2 cytokine profile correlated
with the phenotypic markers of Th1 and Th2 cells, the clones were
tested for the expression of CCR5, which is preferentially
expressed by Th1 cells [17] and of CRTH2 and CCR4, whose
expression characterizes Th2 cells [17,18]. As expected from the
cytokine profile, CD4
+ T cells expressed on their surface both
CRTH2 and CCR4 while CCR5 expression was absent (Fig. 1F).
Combined IL-27 and IL-12 treatment inhibits secretion of
Th2 cytokines and stimulates IFN-c production by CEA
specific CD4
+ T cells
We next tested the possibility to modulate the polarization of the
CEA177–189/355–367-specific Th2 cells by the immunomodulatory
cytokines IL-27 and IL-12.
To this aim we first evaluated the effect of increasing
concentrations of IL-27 or IL-12, as single agents, on the
production by CD4
+ T cells of Th1 and Th2 cytokines in the
presence of the relevant peptide. The addition of IL-27 decreased
in a dose dependent-manner IL-5 and IL-13 production, while
no effect was observed for IL-4 and IFN-c (Fig. 2A). The addition
of IL-12 reached its plateau effect already at the dose of 5 ng/ml
(Fig. 2B): IL-5 production decreased also in the presence of IL-12
while, at difference with IL-27, the effect on IL-13 was marginal
as on IL-4. Importantly, and at difference with IL-27, IFN-c
production was strongly increased (Fig. 2B). These data
demonstrate that both cytokines affect the effector function of
the CEA-specific CD4
+ T cell clones but neither IL-27 nor IL-12,
as single agents, were optimal in modulating their Th
polarization.
Second, we evaluated the effect of the combined treatment with
the two cytokines (Fig. 3). When used at 5 ng/ml, IL-12, as a
single agent, induced 61% inhibition of IL-5 and had no effect on
IL-13 and GM-CSF, while IFN-c production had almost a 10-fold
increase. IL-27 treatment alone at the highest concentration
showed 78%, 30% and 53% inhibition of IL-5, IL-13 and GM-
CSF, respectively; while only 1,4-fold increase in IFN-c produc-
tion. When used in combination at the best concentrations, a
synergistic effect was observed in the inhibition of IL-5 (91%) and
IL-13 (48%), while, as expected from the results of the single
agents, GM-CSF secretion was not further inhibited and IFN-c
production was not further increased.
Modulation of Th2 polarization by IL-12 and IL-27 lasts
after cytokines removal
To verify whether the modulation of Th2 polarization
obtained by the combined treatment with IL-12 and IL-27 was
stable, we designed an experiment in which CEA-specific CD4
+
T cells were first stimulated with the relevant peptide in the
absence or in the presence of IL-12 and IL-27 (5 and 100 ng/ml,
respectively). Second, cells stimulated in the absence of the
cytokines were kept in culture for 14 days in TCM plus IL-2 and
used as controls. Cells treated with the cytokines were divided in
two aliquots and cultured under different conditions for the
following 14 days: in one condition the cytokines were removed
after 2 days and the cells cultured as the controls in TCM plus IL-
2, in the other condition cytokines were kept in culture all the
time and replaced every two to three days. At day 14, cells from
each of the three conditions were tested in a 2-day stimulation
assay with the relevant peptide and cytokine release tested. The
results obtained are shown in Figure 4. Control cells confirmed
production of IL-5, IL-13 and no IFN-c, while cells kept in
culture continuously with the cytokines confirmed 98% and 74%
inhibition of IL-5 and IL-13 production, respectively, and a 11-
fold increase for IFN-c. Importantly, cells in which cytokines
were removed after 2 days of culture still showed 70% and 47%
inhibition in IL-5 and IL-13 production, respectively, and a 5-
fold increase in IFN-c release.
To verify whether the combined treatment also influenced the
Th2 surface phenotype, CD4
+ T cells, which had been re-
stimulated in the presence of the cytokines for 2 days and then
cultured for further seven days in the absence of the cytokines,
were tested for the expression of CRTH2, CCR4 and CCR5. As
shown in Figure 4B, the cells, while maintaining CRTH2 and
CCR4 as in the absence of treatment (Fig. 1F), acquired the
expression of CCR5.
Collectively, these results show that modulation of Th2
polarization of CEA-specific CD4
+ T cell clones obtained with
the combined treatment is lasting, although with reduced
Modulation of Th2 Polarization
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+ T cell clones from pt#15. Profile of cytokine secreted (A). CD4
+ T cells were
cultured with irradiated APC in the presence or the absence of the relevant peptide in a 2-day stimulation assay and the concentration of the
indicated cytokines in the supernatants was determined either by CBA (upper panel) or ELISA (lower panel). The data are representative of at least six
experiments; for ELISA assays, the data are means of duplicate determination6SD. HLA restriction (B). CD4
+ T cells were cultured with irradiated
autologous PBMC or HLA-DR matched LCL, as indicated, in the presence or the absence of the relevant peptide (10 mg/ml) and in the absence or the
presence of anti-HLA-DR, anti-HLA-DP and anti-HLA-DQ mAbs: after 2 days IL-5 was tested. Upper panel: % inhibition was calculated based on IL-5
secretion by CD4
+ T cells in the presence of the relevant peptide (2 ng/ml over 0 ng/ml of background level). The data are representative of two
(upper panel) and four (lower panel) experiments and are means of duplicate determination6SD. Responses significantly higher than the blanks (i.e.,
the basal levels of cytokines secretion from CD4
+ T cells in the presence of LCL only) are indicated as: ***, p,0.001 (determined by unpaired, one-
tailed Student’s t test). Dose-response curves (C). CD4
+ T cells were cultured with titrated doses of the relevant peptide in the presence of irradiated
APC in a 2-day stimulation assay and tested for IL-5 and IL-13 release. The data are means of duplicate determination6SD. Recognition of the native
protein (D). CD4
+ T cells were cultured in the presence of irradiated PBMC, as APC, pulsed with either the relevant peptide (10 mg/ml) as positive
control, or the purified CEA protein (30 mg/ml) or human IgG (30 mg/ml) as negative control in a 2-day stimulation assay and tested for IL-13 release.
The data are means of duplicate determination6SD. Responses significantly higher than the blanks (i.e., the basal levels of cytokines secretion from
CD4
+ T cells in the presence of PBMC only) are indicated as: **, 0.001,p,0.05; ***, p,0.001 (determined by unpaired, one-tailed Student’s t test).
TCRVb expression (E). The test was performed with the IO Test Beta Mark kit. Quadrants were set based on isotype control staining. Surface expression
of Th2 (CRTH2 and CCR4) and Th1 (CCR5) markers (F). Filled histograms represent isotype controls; open histograms samples stained with the indicated
markers.
doi:10.1371/journal.pone.0007234.g001
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functional and phenotypic features of Th0 or both Th1 and Th2
cells.
IL-12 and IL-27 combination enhances Th1 and
modulates Th2 polarization of spontaneous anti-CEA
CD4
+ T cell responses
To verify the effect of combined IL-12 and IL-27 treatment
on the polarization of CEA-specific CD4
+ Tc e l l si nam o r e
physiologic environment and at polyclonal level, CD4
+ T cells
from patient (pt#43) and normal donor (ND#11) were tested in
a 14-days in vitro re-stimulation assay for the recognition of the
relevant peptides in the absence or in the presence of the two
immunomodulatory cytokines(Figure 5).Aspreviously reported
Figure 2. Effect of titrated doses of IL-12 or IL-27 as single agent
on the repertoire of cytokine secreted by CEA177–189/355–367
specific CD4
+ T cells. (A). CD4
+ T cells were cultured with the relevant
peptide and irradiated LCL as APC in the presence of increasing
concentrations of IL-27 (0-0,1-1-10-100 ng/ml); after 2 days the cytokine
release was evaluated by CBA (IL-5 IL-4, and IFN-c) or ELISA (IL-13). The
data for IL-13 are means of duplicate determination6SD. (B). CD4
+ T cells
were cultured and tested, as described above, in the presence of
increasing concentrations of IL-12 (0-5-20 ng/ml). The basal level of
cytokines secretion of CD4
+ T cells in the presence of LCL only was
subtracted from the sample values and was comprised between 0 and
0,018 ng/ml. The data are representative of at least three experiments.
doi:10.1371/journal.pone.0007234.g002
Figure 3. Modulation of Th2 polarization of CEA177–189/355–367
specific CD4
+ T cells by combined IL-12 and IL-27 treatment.
CD4
+ T cells were cultured with the relevant peptide in the absence
(basal) or in the presence of IL-12 (5 ng/ml), as single agent; or IL-27
(100 ng/ml), as single agent; or combined IL-12 and IL-27 in a 2-day
stimulation assay and then tested for cytokine release by CBA (IL-5 and
IFN-c) or ELISA (IL-13 and GM-CSF). The data for IL-13 and GM-CSF are
means of duplicate determination6SD. The basal level of cytokines
secretion of CD4
+ T cells in the presence of LCL only was subtracted from
the sample values and was comprised between 0 and 0,006 ng/ml. The
data are representative of five experiments.
doi:10.1371/journal.pone.0007234.g003
Figure 4. Effects of combined IL-12 and IL-27 given as a single
shot or continuously in culture. (A).C D 4
+ T cells were cultured
with the relevant peptide and either left untreated (peptide) or
treated for 2 days with combined IL-12 (5 ng/ml) and IL-27 (100 ng/
ml) and then washed and left untreated (IL-12+IL-27 (2-days)) or
treated continuously with IL-12 and IL-27 at the same doses for 2
weeks (IL-12+I L - 2 7( 1 4d a y s ) ) .A td a y1 4 ,c e l l sw e r et e s t e di nt h e
presence or the absence of the relevant peptide and the specific IL-5,
IL-13 and IFN-c release in the supernatant tested by ELISA. The data
are means of duplicate determination6SD. The basal level of
cytokines secretion of CD4
+ Tc e l l si nt h ep r e s e n c eo fL C Lo n l yw a s
s u b t r a c t e df r o mt h es a m p l ev a l u e sa n dw a sa sf o l l o w s :I L - 5
(0,09360,006 ng/ml), IL-13 (0,46860,028 ng/ml) and IFN-c (0 ng/ml).
The data are representative of four experiments. (B). Surface
expression of CRTH2, CCR4 CCR5 by CD4
+ T cells after treatment with
combined IL-12+IL-27. Analysis was performed on cells treated for 2
days and then left untreated for a further week. Filled histograms
represent isotype controls; open histograms samples stained with the
indicated markers.
doi:10.1371/journal.pone.0007234.g004
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CD4
+ T cells from pt#43 produced IL-5 in the presence of
CEA425–437;I L - 1 3i nt h ep r e s e n c eo fC E A 568–582;G M - C S Fi n
the presence of CEA568–582 and IFN-c in the presence of
CEA568–582 and, although at a much lower but significant level,
of CEA177–189/355–367 (Fig. 5, left panels, grey bars). The
combination of IL-12 and IL-27 almost abolished IL-5 (99%
inhibition) and IL-13 (76% inhibition) while induced de novo
IFN-c secretion in the presence of CEA425–437, enhanced (9-fold
increase) IFN-c production in the presence of CEA177–189/355–367
and confirmed IFN-c while strongly reduced IL-13 (98% inhibition)
and GM-CSF (80% inhibition) production in the presence of
CEA568–582 (Fig. 5, left panels, black bars). As previously reported [3],
in the absence of the immunomodulatory cytokines CD4
+ T cells
from ND#11 showed significant proliferation [3] and very little
amount of IFN-c secretion in the presence of CEA99–111, while no
significant production of IL-5 and GM-CSF was observed in the
presence of any peptide (Fig. 5, right panels, grey bars). IL-13 release
was not tested. Cytokine treatment strongly augmented (23-fold
increase) IFN-c release against CEA99–111, while, as expected, no
effect on IL-5 and GM-CSF production was observed (Fig. 5, right
panels, black bars). In both cases, the two cytokines induced
modulation of Th2 or amplification of Th1 responses that were
already present, although at very low level, in the absence of the
cytokines combination, while there was no evidence of de-novo
specific recognition of CEA peptides.
Collectively, these results suggest that IL-12 and IL-27 promote
functional modulation of Th2-type and amplification of pre-
existing Th1-type anti-CEA responses.
Discussion
In the present study, we report that the association of the
immunomodulating cytokines IL-12 and IL-27 is able to modulate
the functional polarization of anti-CEA Th2 CD4
+ T cells from
PC patients and to enhance pre-existing Th1 type anti-CEA CD4
+
T cells.
We show that treatment with IL-27 as a single agent inhibited
both IL-5 and IL-13 release by CEA-specific Th2 cells. This
confirms in the human system a previous report that described
I L - 2 7a sa b l et os u p p r e s sT h 2c y t o k i n e sp r o d u c t i o nf r o min vitro
polarized mouse Th2 cells [12]; but, at difference with this
report, in our system in which we deal with bona fide in vivo
polarized CD4
+ T cells IL-27 had no effect on IFN-c secretion.
Importantly,we also revealed a new function for IL-27 that is the
inhibition of GM-CSF production. When IL-12 was used as a
single agent, it strongly enhanced IFN-c production, while had
only a marginal effect in suppressing the release of Th2
cytokines, and of IL-13 in particular and no effect on GM-
CSF. This is also at difference with previous reports [7,8], in
which IL-12 was shown to revert polarization of human allergen
specific Th2 cells by inducing IFN-c and inhibition of IL-4
production. Indeed, in the case of our clones IL-4, which
however was not produced in high amounts, was not inhibited
neither by IL-27 nor IL-12. The only Th2 cytokine affected by
IL-12 was IL-5; this function was also previously reported for T
cell clones obtained from the bronchoalveolar lavage of
asthmatic patients [19].
Collectively, we show that in our system IL-12 and IL-27
have non redundant roles in modulating the polarization of
established CEA-specific Th2 CD4
+ Tc e l l sa n dt h a tm o d u l a -
tion of the functional and phenotypic Th2 polarization of anti-
tumor CD4
+ effectors into a Th0 type was obtained only in the
presence of the combined synergistic treatment with the two
Figure 5. Combined treatment with IL-12 and IL-27 modulates
polarization of Th2 and enhances IFN-c production by pre-
existing Th1 anti-CEA CD4
+ T cells. CD4
+ T cells from pt#43 and
ND#11 were cultured in five replicates, as described in Materials and
Methods, with the responsive CEA peptides, in the absence (grey bars)
or in the presence (black bars) of the combined treatment with IL-12
(5 ng/ml) plus IL-27 (100 ng/ml). After 14 days, IL-5, IL-13, GM-CSF and
IFN-c release was tested by ELISA. Data reported are means of duplicate
determination6SD. Dashed lines identify the basal level of cytokine
secretion in the presence of APC only. n.d.=not determined.
doi:10.1371/journal.pone.0007234.g005
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in the case of the clones, mostly functional with the induction of
a rather peculiar phenotype where CCR4, CRTH2 and CCR5
expression coexisted (i.e., not typical of either Th1 or Th0 cells).
Preliminary experiments (data not shown), in which we
evaluated cytokines’ production at single cell level by intracel-
lular staining, indicated that: i) IL-27 alone did not affect the
percentage of IL-5 and IL-13 or IFN-c producing cells both as
single positive and double positive; and ii) IL-12 alone or the
combination of the two cytokines induced a percentage of CD4
+
T cells producing both Th2 cytokines and IFN-c without
r e d u c t i o ni nt h en u m b e ro fC D 4
+ T cells producing Th2
cytokines. These results along with the previous ones on
cytokine secretion in the supernatants exclude that the effect
of IL-12 on IFN-c up-regulation is due to a subpopulation of
Th1 cells that becomes preferentially expanded and suggest that
the combination of IL-27 and IL-12 induces a reduction of Th2
cytokines secretion per single cell and reverts a small population
of CD4
+ Th2 cells, which then produce also high levels of IFN-
c, to a Th0 type. Further experiments are needed to better
define the mechanism of action of the two cytokines both as
single agent and in combination.
The effects of modulation of Th2 polarization seemed more
effective for CEA-specific polyclonal CD4
+ T cells where
combined treatment was able to almost completely abolish IL-13
and GM-CSF production (Fig. 5). Although, we cannot exclude
that in the latter case treatment with the cytokines might have
affected not only the effectors but also the APC, which in turn
might have further changed the cytokine milieu. To address this
issue future studies should compare gene expression of different
APC at basal level and after modulation with different cytokines’
combination.
There are two main positive effects correlated to the modulation
of the Th2 and enhancement of Th1 polarization of CEA-specific
CD4
+ T cells in PC. First, on the anti-tumor immunity: indeed, in
human tumors a skew towards Th2 type of tumor-specific CD4
+ T
cells has been described in patients with advanced malignancies
[20,21,22], while high levels of infiltrating Th1 cells in the tumors
correlate with a better prognosis [23]. Second, on the tumor
microenvironment, as fibrinogenesis and recruitment of myeloid
suppressor cells are potentially inhibited. Indeed, Th2 cytokines
and IL-13 in particular are strongly associated with stroma
deposition, which is a peculiar feature of PC and is potentially
involved in tumor progression, while IFN-c suppresses collagen
synthesis by fibroblasts [4]. Furthermore, high levels of GM-CSF
in anti-tumor vaccines enhance the recruitment of myeloid
suppressor cells, thus potentially favoring immune-escape of the
tumor [24,25].
Overall, our results demonstrate that in vivo polarized Th2
CD4
+ T cells specific for a tumor-associated antigen from PC
patients are endowed with plasticity, and support further studies
aimed at investigating the possible clinical application of the
combination of IL-12 and IL-27 as a treatment for pancreatic
cancer both as cytokines delivery and possibly for reprogramming
tumor antigen specific T cells prior to adoptive immunotherapy.
Treatment with systemic IL-12 of mouse cancer models has
been shown to have a strong anti-tumor effect [26,27]. However,
systemic administration of IL-12, although stimulated anti-tumor
immunity, had only minimal clinical efficacy in the presence of
relevant side effects [28,29]. Attempts to achieve IL-12 production
only at the tumor site in melanoma and gastrointestinal
carcinomas resulted instead in the absence of significant toxicity
and in increased clinical responses, which correlated with
increased inflammation [30,31,32]. In mouse models also IL-27
had a strong anti-tumor effect, which was enhanced by the
presence of IL-12 [33,34,35,36].
To avoid systemic toxicity, strategies to selectively deliver
various therapeutic compounds, including IL-12, to the tumor by
tumor-specific antibodies or to the tumor vasculature have been
recently developed [37,38]. Of note, some of these strategies are
directed towards tenascin, which is a component of the
extracellular matrix and it is produced by pancreatic stellate cells,
possibly under the influence of soluble factors released by tumor
cells [39]. Therefore, tenascin could represent an interesting target
for tumor-delivery of IL-12 and IL-27 in PC.
The advantages of tumor targeted delivery of combined IL-12
and IL-27 in PC would be the modulation of the tumor
microenvironment not only through their known effect on resident
antigen presenting cells (and therefore on the de-novo priming of
new Th1 effectors in the draining lymph nodes) but also directly
on the modulation of the cytokines secreted by Th2 GATA-3+
infiltrating T cell effectors already present in the tumor by
diminishing their negative effects on fibrinogenesis and recruit-
ment of immunosuppressive myeloid dendritic cells, in the absence
of systemic toxicity.
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